Education
About Us
Working with TipRanks
Follow Us
Rigel (RIGL)
NASDAQ:RIGL
RIGL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$13.57 - $43.72
Previous CloseN/A
Volume99.93K
Average Volume (3M)744.25K
Market Cap
$505.12M
Enterprise Value$292.84M
Total Cash (Recent Filing)$108.38M
Total Debt (Recent Filing)$61.04M
Price to Earnings (P/E)5.2
Beta2.22
Next Earnings
Nov 06, 2025EPS Estimate
0.9Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.28
Shares Outstanding17,937,340
10 Day Avg. Volume795,711
30 Day Avg. Volume744,246
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.58
Enterprise Value/Revenue1.09
Enterprise Value/Gross Profit1.19
Enterprise Value/Ebitda2.68
Forecast
1Y Price Target
$42.50Price Target Upside51.14% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Clinical TrialsARROW trial wraps with strong efficacy and safety results for GAVRETO.
EarningsRigel Pharmaceuticals reported higher-than-expected revenue growth, primarily driven by stronger-than-projected sales of Gavreto and Tavalisse.
Market AccessImproved patient affordability under the Inflation Reduction Act facilitates access to oral therapies like Tavalisse.
Bears Say
Strategic DecisionsRigel decided not to exercise its opt-in right for ocadusertib under its agreement with Eli Lilly, based on internal strategic prioritization.
Rigel News
RIGL FAQ
What was Rigel’s price range in the past 12 months?
Rigel lowest stock price was $13.57 and its highest was $43.72 in the past 12 months.
What is Rigel’s market cap?
Rigel’s market cap is $505.12M.
When is Rigel’s upcoming earnings report date?
Rigel’s upcoming earnings report date is Nov 06, 2025 which is in 34 days.
How were Rigel’s earnings last quarter?
Rigel released its earnings results on Aug 05, 2025. The company reported $3.28 earnings per share for the quarter, beating the consensus estimate of $2.58 by $0.7.
Is Rigel overvalued?
According to Wall Street analysts Rigel’s price is currently Undervalued.
Does Rigel pay dividends?
Rigel does not currently pay dividends.
What is Rigel’s EPS estimate?
Rigel’s EPS estimate is 0.9.
How many shares outstanding does Rigel have?
Rigel has 17,937,340 shares outstanding.
What happened to Rigel’s price movement after its last earnings report?
Rigel reported an EPS of $3.28 in its last earnings report, beating expectations of $2.58. Following the earnings report the stock price went up 22.979%.
Which hedge fund is a major shareholder of Rigel?
Currently, no hedge funds are holding shares in RIGL
Rigel Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$42.50 (51.14% Upside)
$42.50 (51.14% Upside)
Blogger Sentiment
Bullish
RIGL Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 1.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 10.8%
Last 30 Days ▲ 0.5%
Last 30 Days ▲ 0.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
72.02%
12-Months-Change
Fundamentals
Return on Equity
376.09%
Trailing 12-Months
Asset Growth
61.00%
Trailing 12-Months
Company Description
Rigel
Rigel Pharmaceuticals, Inc. (RIGL) is a biotechnology company focused on the discovery and development of innovative therapies for patients with rare diseases and cancer. The company operates primarily in the biopharmaceutical sector and is known for its targeted treatments that leverage its expertise in small-molecule drug development. Rigel's core products include medications that address hematologic disorders and oncology, with a focus on advancing its pipeline of candidates through various stages of clinical trials.
RIGL Company Deck
RIGL Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call was overwhelmingly positive, highlighting significant sales growth across all products, increased revenue guidance, strong financial performance, and successful market expansion strategies. While there was a minor reevaluation in patient responder data, it did not significantly detract from the overall positive performance and outlook for the company.View all RIGL earnings summariesRIGL Stock 12 Month Forecast
Average Price Target
$42.50
▲(51.14% Upside)
Technical Analysis
Lexicon Pharmaceuticals
―
Verastem
―
RegenXBio
―
Bicycle Therapeutics
―
Opthea Limited Sponsored ADR
―
Ownership Overview
2.60% Insiders
26.37% Mutual Funds
27.78% Other Institutional Investors
29.10% Public Companies and
Individual Investors